Actinogen Medical Limited
ACW
Rank in Stocks
#18507
Actinogen Medical Limited is an Australian biotechnology company dedicated to... Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11Γ-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
Share Price
$0.03391731
Last synced: 2026-11-10
Market Cap
$131.40M
Change (1 day)
-2.00%
Change (1 year)
20.87%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Actinogen Medical Limited (ACW)
Category
Healthcare
Operating Margin for Actinogen Medical Limited (ACW)
Operating Margin as of November 2026 TTM: 0.00%
According to Actinogen Medical Limited's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of -272.01%.
Operating Margin history for Actinogen Medical Limited from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | -272.01% | 110.40% |
| 2024 | -129.28% | -60.19% |
| 2023 | -324.74% | -10.27% |
| 2022 | -361.90% | 21.62% |
| 2021 | -297.57% | 17.41% |
| 2020 | -253.44% | 28.28% |
| 2019 | -197.57% | -31.80% |
| 2018 | -289.70% | -10.80% |
| 2017 | -324.79% | 69.37% |
| 2016 | -191.76% | -94.58% |
| 2015 | -3,535.55% | 1,436.39% |
| 2014 | -230.12% | -98.44% |
| 2013 | -14,745.10% | 585.03% |
| 2012 | -2,152.49% | 93.43% |
| 2011 | -1,112.80% | 2.73% |
| 2010 | -1,083.19% | 56.97% |
| 2009 | -690.08% | 86.28% |
| 2008 | -370.45% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Actinogen Medical Limited's operating margin
What was Actinogen Medical Limited's operating margin in 2025?
In 2025, Actinogen Medical Limited's operating margin was -272.01%, compared with -129.28% in 2024.
How has Actinogen Medical Limited's operating margin changed since 2020?
From 2020 to 2025, Actinogen Medical Limited's operating margin was highest in 2024 (-129.28%) and lowest in 2022 (-361.90%).
How does Actinogen Medical Limited's operating margin compare with similar companies?
Actinogen Medical Limited's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.